Five biopharma companies will soon be testing their lung cancer compounds in a very different type of clinical trial. The Lung Cancer Master Protocol will test multiple novel drugs simultaneously ...

As compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer (NSCLC), the biomarker-driven Lung Cancer Master Protocol (Lung-MAP) has enrolled higher percentages of ...

Pilot project will bring drug companies together to test targeted lung-cancer therapies. You have full access to this article via your institution. In the push to match medical therapies to the ...

Biomarker-driven master protocols represent a new paradigm in oncology clinical trials, but their complex designs and wide-ranging genomic results returned can be difficult to communicate to ...